Pulmonary complications often fatal in systemic JIA

November 19, 2012
Pulmonary complications often fatal in systemic JIA
Pulmonary complications are under-recognized in systemic juvenile idiopathic arthritis, and are often fatal, according to a study published online Nov. 8 in Arthritis Care & Research.

(HealthDay)—Pulmonary complications are under-recognized in systemic juvenile idiopathic arthritis (sJIA), and are often fatal, according to a study published online Nov. 8 in Arthritis Care & Research.

Yukiko Kimura, M.D., from the Hackensack University Medical Center in New Jersey, and colleagues utilized an electronic listserv to identify sJIA patients who developed pulmonary artery hypertension (PAH), interstitial lung disease (ILD), and/or alveolar proteinosis (AP). The 25 patients were compared to a sJIA cohort of patients from the Childhood and Rheumatology Research Alliance (CARRA; 389 participants).

The researchers found that, compared with the CARRA cohort, patients were significantly more likely to be female; have more systemic features; and to have been exposed to an interleukin-1 (IL-1) inhibitor, tocilizumab, infliximab, corticosteroids, intravenous immunoglobulin, cyclosporine, and cyclophosphamide. During the course of their disease, 80 percent of the patients had macrophage activation syndrome (MAS), and 60 percent had MAS at pulmonary diagnosis. PAH was seen in 16 patients, ILD in seven, and AP in five patients. At pulmonary symptom onset, 68 percent of patients were taking or recently (one month or less) discontinued a biologic agent and 48 percent were taking anti-IL-1 therapy. At a mean of 8.8 months following pulmonary diagnosis, 68 percent of died.

"PAH, AP and ILD are under-recognized of sJIA which are frequently fatal," the authors write. "These may be the result of severe uncontrolled systemic disease activity, and may be influenced by medication exposure."

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: New study may lead to quicker diagnosis, improved treatment for fatal lung disease

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Standardized treatment plans developed for new-onset JIA

July 3, 2012

(HealthDay) -- Four standardized consensus treatment plans (CTPs) have been developed for patients with new-onset systemic juvenile idiopathic arthritis (JIA), according to research published in the July issue of Arthritis ...

Not all juvenile arthritis is the same

October 22, 2012

Systemic juvenile idiopathic arthritis (SJIA) is currently classified as a subtype of juvenile idiopathic arthritis but with the addition of systemic inflammation often resulting in fever, rash and serositis. New research ...

Recommended for you

Team finds gene that confirms existence of psoriatic arthritis

February 5, 2015

PsA is a common form of inflammatory form of arthritis causing pain and stiffness in joints and tendons that can lead to joint damage. Nearly all patients with PsA also have skin psoriasis and, in many cases, the skin disease ...

Blocking one receptor could halt rheumatoid arthritis

September 10, 2014

Researchers at the University of Illinois at Chicago College of Medicine have shown for the first time how the activation of a receptor provokes the inflammation and bone degradation of rheumatoid arthritis—and that activation ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.